What Galectin Therapeutics Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 3 |
| Sells | 0 | 65 |
| Total trades | 2 | 124 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 34,376,167 | 35,677,783 |
| Disposed | 0 | 1,868,687 |
| Net activity | +34,376,167 | +33,809,096 |
Common stock only — 2 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Uihlein Richard E | Director | Jul 31 | Exercise / conversion · M | +2,550,932 | $4.05 | +$10.3M | 44,713,843 |
| Uihlein Richard E | Director | Jul 31 | Exercise / conversion · M | +31,825,235 | $3.00 | +$95.5M | 42,162,911 |
| Jamil Khurram | Chief Medical Officer | Jul 14 | Open-market sale · S | −16,250 | $5.13 | −$83.3K | 0 |
| Jamil Khurram | Chief Medical Officer | Jul 14 | Exercise / conversion · M | +16,250 | $3.04 | +$49.4K | 16,250 |
| Jamil Khurram | Chief Medical Officer | Jun 29 | Open-market sale · S | −47,467 | $5.04 | −$239K | 0 |
| Jamil Khurram | Chief Medical Officer | Jun 29 | Exercise / conversion · M | +47,467 | $2.50 | +$119K | 47,467 |
| Shlevin Harold H. | Director | Jun 29 | Open-market sale · S | −22,268 | $5.04 | −$112K | 6,500 |
| Shlevin Harold H. | Director | Jun 29 | Exercise / conversion · M | +22,268 | $1.23 | +$27.4K | 28,768 |
| Jamil Khurram | Chief Medical Officer | Jun 26 | Open-market sale · S | −2,533 | $5.00 | −$12.7K | 0 |
| Jamil Khurram | Chief Medical Officer | Jun 26 | Exercise / conversion · M | +2,533 | $2.50 | +$6.33K | 2,533 |
| Jamil Khurram | Chief Medical Officer | Jun 26 | Open-market sale · S | −2,037 | $5.00 | −$10.2K | 0 |
| Jamil Khurram | Chief Medical Officer | Jun 26 | Exercise / conversion · M | +2,037 | $2.20 | +$4.48K | 2,037 |
| Shlevin Harold H. | Director | Jun 26 | Open-market sale · S | −7,732 | $5.00 | −$38.7K | 6,500 |
| Shlevin Harold H. | Director | Jun 26 | Exercise / conversion · M | +7,732 | $1.23 | +$9.51K | 14,232 |
| Jamil Khurram | Chief Medical Officer | Jun 23 | Open-market sale · S | −7,557 | $3.14 | −$23.7K | 0 |
| Jamil Khurram | Chief Medical Officer | Jun 23 | Exercise / conversion · M | +7,557 | $1.23 | +$9.3K | 7,557 |
| Jamil Khurram | Chief Medical Officer | May 26 | Open-market sale · S | −568 | $3.10 | −$1.76K | 0 |
| Jamil Khurram | Chief Medical Officer | May 26 | Exercise / conversion · M | +568 | $1.23 | +$699 | 568 |
| Eldred Kary | Director | Feb 06 | Open-market buy · P | +300 | $2.70 | +$810 | 65,682 |
| Uihlein Richard E | Director | Jan 16 | Grant / award · A | +13,158 | $3.04 | +$40K | 10,332,676 |
Loading...